Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506231 | 0.90 | KMT2A (0.37) | MAPTKMT2APOLBALDH1A1GAA | |
| SCHEMBL6510626 | 0.88 | TDP1 (0.34) | KMT2APOLBALDH1A1HPGDGAA | |
| SCHEMBL6508566 | 0.86 | ALDH1A1 (0.38) | MAPTKMT2APOLBALDH1A1HPGD | |
| SCHEMBL6508814 | 0.84 | ATF1 (0.30) | — | |
| SCHEMBL6503874 | 0.84 | KMT2A (0.36) | KMT2AALDH1A1HPGD | |
| SCHEMBL6508683 | 0.84 | SSTR3 (0.31) | — | |
| SCHEMBL6499218 | 0.84 | LMNA (0.35) | KMT2AALDH1A1HPGDNPSR1GAA | |
| SCHEMBL6501528 | 0.83 | L3MBTL1 (0.36) | MAPTNPSR1LMNATP53 | |
| SCHEMBL6506960 | 0.82 | CES2 (0.34) | — | |
| SCHEMBL6506058 | 0.82 | SCN8A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | MAPT 3607/4885KMT2A 3213/4885POLB 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.